The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | MRD status in lung cancer
Federico Cappuzzo, MD, PhD, AUSL della Romagna-Ravenna, Ravenna, Italy, discusses the utility of minimal residual disease (MRD) status in lung cancer treatment. This approach can be used for various purposes, including screening, early detection and defining patients at risk for relapse following surgery and monitoring treatment response. Data on patients with early-stage disease, as well as data assessing MRD in patients with stage II or III lung cancer following surgery, will be presented at the IASLC 2022 World Conference on Lung Cancer congress (WCLC). This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
